Taro Shibuki | Clinical Trials | Best Researcher Award

Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. πŸŽ“ He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. πŸ₯ His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. πŸ”βœ¨

Publication Profile

orcid

Education

Dr. Taro Shibuki πŸŽ“ is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies πŸ“–, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards πŸ† for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. πŸš€

Research and Innovations

Dr. Taro Shibuki πŸ”¬ is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) πŸ“‘, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach πŸš€, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. πŸ₯

Scientific Contributions

Dr. Taro Shibuki πŸ“š is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics πŸ”, and metabolomics πŸ§ͺ to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) πŸ₯ assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. πŸš€

Editorial Roles

Dr. Taro Shibuki βš•οΈ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) πŸ₯ plays a crucial role in clinical innovation. His research in drug development πŸ’Š and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress πŸ”¬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. πŸš€

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies πŸ₯. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors πŸ† for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases πŸ”¬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. πŸš€

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology πŸ”¬, with a particular focus on precision medicine 🧬, pancreatic cancer πŸ₯, and biliary tract cancer πŸ§‘β€βš•οΈ. His work involves optimizing chemotherapy πŸ’Š and developing advanced stent deployment techniques πŸ—οΈ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects πŸ§‘β€πŸ”¬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics πŸ₯ and therapeutic strategies πŸ’‘, striving for a quantum leap in oncology πŸš€ by integrating molecular profiling 🧬 and cutting-edge clinical approaches πŸ₯.

Publication Top Notes

Dr. John Thometz|Pharmaceutical Analysis|Excellence in Reach Award

Dr.JohnThometz|Pharmaceutical Analysis|Excellence in Reach Award

Dr. John Thometz at Medical College of WI,United States

PROFILEΒ Β 

 

Scopus

🏫 Early Academic Pursuits

Dr. John G. Thometz embarked on his academic journey in medical sciences with a strong foundation at Northwestern University, where he earned a Bachelor of Science in Medicine (B.S.M.) in 1973. His commitment to global understanding in medicine took him to Loyola University in Rome, Italy, where he furthered his education in 1974. Dr. Thometz then completed his medical degree (M.D.) at Northwestern Medical School in 1978, after which he was awarded a surgical scholarship at Addenbrooke’s Hospital in Cambridge, England. These experiences laid the groundwork for his illustrious career in orthopedic surgery, with a specialization in pediatric orthopedics.

🩺 Professional Endeavors

Dr. Thometz’s professional career began with intensive training, including a general surgery internship at Loyola University in Chicago, followed by a residency in orthopedic surgery at Northwestern University. His desire to make an impact in pediatric orthopedics led him to Harvard University’s Children’s Hospital, where he completed a fellowship in 1985. Soon after, he joined the Medical College of Wisconsin, where he served as Assistant Professor in the Department of Orthopaedic Surgery. Over the years, his dedication and expertise were recognized with progressive appointments, eventually reaching the rank of Professor in 2000. Dr. Thometz has also held a long-standing role as Adjunct Professor at Marquette University’s Orthopaedic and Rehabilitation Engineering Center (OREC), bridging academic and clinical disciplines.

πŸ”¬ Contributions and Research Focus

Dr. Thometz’s research has significantly advanced pediatric orthopedics, with a focus on developing innovative treatments and technologies for children with musculoskeletal disorders. His research spans early-onset scoliosis, cerebral palsy, and spinal deformities. His projects include contributions to critical studies on casting versus bracing in scoliosis treatment, funded by the Orthopaedic Research and Education Foundation (OREF), and a novel study on dynamic pedorthosis for clubfoot correction. In collaboration with the U.S. Department of Health and Human Services and the National Institute on Disability and Rehabilitation Research (NIDILRR), Dr. Thometz has led initiatives to train physicians and engineers in advanced pediatric rehabilitation.

πŸ… Accolades and Recognition

Dr. Thometz’s dedication to orthopedic surgery has been widely recognized through numerous accolades, highlighting his commitment to excellence in both teaching and clinical practice. He was named Teacher of the Year twice by the Medical College of Wisconsin’s Department of Orthopaedic Surgery (1988, 2000) and awarded the prestigious Louis A. Goldstein Award for Best Clinical Poster Presentation at the 2010 Scoliosis Research Society Annual Meeting. His expertise has also earned him a consistent place on the Best Doctors in America list, as well as recognition by MKE Lifestyle Magazine for multiple years, underscoring his impact in Milwaukee and beyond.

🌍 Impact and Influence

Beyond his immediate clinical and teaching roles, Dr. Thometz has made substantial contributions to the orthopedic community nationally and internationally. He is an active member and fellow of esteemed organizations, including the American Academy of Orthopaedic Surgeons, the Pediatric Orthopaedic Society of North America, and the Scoliosis Research Society. His work in these societies has focused on advancing pediatric orthopedics and influencing guidelines on nonoperative management strategies, particularly in scoliosis care.

πŸ›οΈ Legacy and Future Contributions

As a pioneer in pediatric orthopedic surgery, Dr. Thometz has contributed to foundational research and mentorship that continue to shape the field. His leadership as Medical Director of Pediatric Orthopedic Surgery at the Children’s Hospital of Wisconsin spanned three decades, culminating in his role as Emeritus Medical Director for the Spina Bifida program. Dr. Thometz’s work on advanced rehabilitation technologies and orthopedic interventions continues through his position as Co-Program Director of the Advanced Rehabilitation Research Training (ARRT) in Pediatric Mobility. His legacy is further carried on by his students and residents, many of whom have become leaders in orthopedics. Dr. Thometz’s future contributions are poised to focus on guiding new research, particularly in enhancing pediatric mobility and rehabilitation, with a continued commitment to improving the quality of life for children globally.

πŸŽ“PublicationΒ 

Analysis of adolescent idiopathic scoliosis population for Surgical Site Infection Risk Factors

  • AuthorsΒ  Β :Fletcher, J., Liu, X.-C., Thometz, J.G.
  • JournalΒ  Β  :Journal of Orthopaedics
  • YearΒ  Β  Β  Β  Β :2025

Correlation of transverse rotation of the spine using surface topography and 3D reconstructive radiography in children with idiopathic scoliosis

  • AuthorsΒ  Β : Patel, M., Liu, X.-C., Tassone, C., Yang, K., Thometz, J.
  • JournalΒ  Β  :Spine Deformity
  • YearΒ  Β  Β  Β  Β :2024

3D Back Contour Metrics in Predicting Idiopathic Scoliosis Progression: Retrospective Cohort Analysis, Case Series Report and Proof of Concept

  • AuthorsΒ  Β : Patel, M., Liu, X.-C., Yang, K., Escott, B., Thometz, J.
  • JournalΒ  Β  :Children,
  • YearΒ  Β  Β  Β  Β :2024

Prophylactic Spinal Cord Untethering in Children with Spinal Dysraphism Undergoing Thoracolumbar Fusion for Scoliosis

  • AuthorsΒ  Β :Bureau, B.L., Sherburne, E., Thometz, J.G., Foy, A.B.
  • JournalΒ  Β  :World Neurosurgery
  • YearΒ  Β  Β  Β  Β :2023

Preoperative left shoulder elevation > 1 cm is predictive of severe postoperative shoulder imbalance in early onset idiopathic scoliosis patients treated with growth-friendly instrumentation

  • AuthorsΒ  Β :Li, Y., Yang, D., Bergman, R., Yazici, M., Zhang, T.J.
  • JournalΒ  Β  :Spine Deformity
  • YearΒ  Β  Β  Β  Β :2023

Dr. Marc Bender|Immunotherapy |Best Researcher Award

Dr. Marc Bender|Pharmaceutical Chemistry |Best Researcher Award|

Dr. Marc Bender at abriz University of Medical Sciences, Iran

PROFILEΒ Β 

orcid

Early Academic Pursuits πŸ“š

Marc Bender’s academic journey began with a strong foundation in molecular biology, earning a (link unavailable) and (link unavailable) from UniversitΓ€t Hamburg. He furthered his expertise by pursuing a doctorate in skin cancer research at the department of dermatology, Elbe Klinikum Buxtehude. His thesis focused on elucidating molecular mechanisms, particularly epigenetic regulation via miRNAs, involved in tumor progression of cutaneous squamous cell carcinoma.

Professional Endeavors πŸ’Ό

As a data scientist, Marc contributed to the European melanoma registry (EUMelaReg), evaluating retrospective data for real-world clinical trials. This experience deepened his understanding of melanoma and immunotherapy, and he developed skills in statistical methods and programming. His professional endeavors have been marked by a commitment to advancing cancer research and treatment.

Contributions and Research Focus πŸ”¬

Marc’s research focus encompasses various aspects of skin cancer, including:

– Investigating effects of combined UVA, UVB, visible light, and infrared radiation on human skin cells (KAUVIR)
– Examining the influence of UVA and UVB irradiation on human dermal stem cells (UV-DHDS)
– Comparing treatments for melanoma, including anti-PD1 monotherapy and BRAF/MEK inhibitor treatment (PDSeq and EMRSeq)
– Analyzing immune checkpoint inhibitor maintenance treatment after achieving a partial or complete response (EUMelaReg)

Accolades and Recognition πŸ†

Marc’s work has been recognized through publications in esteemed journals, including:

– Journal of Cancer Research and Clinical Oncology
– Journal of Photochemistry and Photobiology B Biology
– Cancers (MDPI)
– Journal of Clinical Oncology (conference paper)
– Annals of Oncology (conference paper)

Impact and Influence 🌟

Marc’s research has contributed significantly to the understanding of skin cancer mechanisms and treatment options. His work has:

– Advanced knowledge of miRNA expression and its association with tumor progression
– Investigated treatment adherence in patients with stage III melanoma
– Compared outcomes of different treatment approaches for metastatic melanoma

Legacy and Future Contributions 🌱

As a dedicated researcher, Marc continues to contribute to the field of skin cancer research. His future endeavors will likely focus on:

– Furthering understanding of molecular mechanisms in skin cancer
– Developing innovative treatment approaches
– Collaborating with international researchers to advance cancer research

Marc’s legacy will be marked by his commitment to advancing cancer research, improving treatment options, and enhancing patient outcomes. His work will continue to influence the scientific community, inspiring future generationsΒ ofΒ researchers.

πŸŽ“PublicationΒ 

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

  • AuthorsΒ  Β :Β Marc Bender
  • JournalΒ  Β  :Cancers
  • YearΒ  Β  Β  Β  Β :2022

UVB damage response of dermal stem cells as melanocyte precursors compared to keratinocytes, melanocytes, and fibroblasts from human foreskin

  • AuthorsΒ  Β :Marc Bender
  • JournalΒ  Β  :Photochemistry and Photobiology B: Biology
  • YearΒ  Β  Β  Β  Β :2021

UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines

  • AuthorsΒ  Β : Marc Bender
  • JournalΒ  Β  :Cancer Research and Clinical Oncologyy
  • YearΒ  Β  Β  Β  Β :2020

 

Ms.Megan Leonard, Supplementation,Best Researcher Award-1126

Ms.Megan Leonard, Supplementation ,Best Researcher Award

Ms.Megan Leonard, at Texas A&M University,United States

Author Profile

πŸŽ“Β Education

Doctor of Philosophy – Kinesiology
Texas A&M University

  • Emphasis: Exercise Physiology, Supplement Nutrition, Exercise and Dietary Psycho-Physiology
  • Dissertation: Assessment of Nootropic Properties of Upcoming and Novel Ingredients Proposed to Improve Cognitive Function and Performance
  • Faculty Advisor: Dr. Richard B. Kreider
  • Expected Graduation: May 2024 – ABD

Master of Science – Clinical Exercise Science
Liberty University

  • Faculty Advisor: Dr. Andrew Bosak
  • Graduation Date: December 2019

Bachelor of Science – Kinesiology
University of North Texas

  • Kinesiology, Health Promotion, and Recreation
  • Graduation Date: May 2016

πŸ’ΌΒ Professional Experience

Exercise and Sports Nutrition Laboratory Researcher / Study Coordinator
Texas A&M University

  • July 2020 – Present

Huffines Institute Volunteer Assistant – Tactical Personnel Research
Texas A&M University

  • Spring 2021 – Present

Graduate Teaching Assistant
Motor Control and Motor Learning Laboratory (KINE), Texas A&M University

  • January 2022 – Present

Graduate Teaching Assistant
Physical Education Activity Program (PEAP), Texas A&M University

  • August 2021 – August 2022

Phlebotomist / Research Assistant
Texas A&M University

  • Spring 2023 – Fall 2023

Rehab Specialist
Alpha Sports Chiropractic

  • May 2021 – July 2021

Track & Field Sport Science Intern
Texas A&M University

  • January 2021 – July 2021

Research Assistant
Texas A&M University

  • November 2020 – April 2021

CrossFit Coach and Tactical Coach
Row and Oak CrossFit

  • November 2019 – March 2020

Certified Recovery Specialist – Clinical Leader

  • December 2017 – August 2020

πŸ”¬Β Research Interests

  • Exercise Physiology
  • Supplement Nutrition
  • Cognitive Function and Performance
  • Dietary Psycho-Physiology
  • Human Clinical Research

πŸŽ“Publication Top Noted:

Paper Title : Effects of Supplementation with Microalgae Extract from Phaeodactylum tricornutum (Mi136) to Support Benefits from a Weight Management Intervention in Overweight Women
  • Authors:Dickerson, B., Maury, J., Jenkins, V., Rasmussen, C.J., Kreider, R.B.
  • Journal: Nutrients
  • Year: 2024
Paper Title :Paraxanthine provides greater improvement in cognitive function than caffeine after performing a 10-km run
    • Authors:Yoo, C., Xing, D., Gonzalez, D.E., Rasmussen, C.J., Kreider, R.B.
    • Journal:Journal of the International Society of Sports Nutrition
    • Year: 2024
Paper Title :Pharmacokinetic Analyses of Liposomal and Non-Liposomal Multivitamin/Mineral Formulations
  • Authors: Ko, J., Yoo, C., Xing, D., Rasmussen, C.J., Kreider, R.B.
  • Journal:Nutrients
  • Year: 2023
Paper Title :Ethyl chloroformate mediated gas chromatographic-mass spectrometric biomonitoring of acidic biomarkers of occupational exposure and endogenous metabolites in human urine
  • Authors: Leonard, M., Maury, J., Dickerson, B., Rasmussen, C.J., Kreider, R.B.
  • Journal: Nutrients
  • Year: 2023
Paper Title :Risk Factors for Cardiometabolic Disease in Professional Firefighters
  • Authors:McAllister, M.J., Gonzalez, D.E., Leonard, M., Pence, J., Martin, S.E.
  • Journal: Journal of Occupational and Environmental Medicine
  • Year: 2023

Assist Prof Dr. Lili Xu, Drug Discovery and Development ,Best Researcher Award

Assist Prof Dr. Lili Xu, Drug Discovery and Development ,Best Researcher Award

Assist Prof Dr. Lili Xu, at China Pharmaceutical University,China

Author Profile

πŸŽ“ Academic and Professional Background:

Lili Xu, Ph.D., earned her degree in Pharmaceutical Chemistry and Biology from China Pharmaceutical University in 2017. She conducted postdoctoral research at the same institution until July 2021 when she was promoted to Associate Researcher. She leads two projects funded by the National Natural Science Foundation of China and two by the Natural Science Foundation of Jiangsu Province. With over 40 SCI papers and six patents, she’s received awards like the Shimadzu Young Scholar, Gold Prize of the Macedonia Invention, and Silver Prize of the Geneva Invention Award.

πŸ”¬ Research and Innovations:

Completed/Ongoing Research Projects:

  • National Natural Science Foundation of China, General Program: Screening, design, and synthesis of novel inhibitors that interfere with the formation of NEK7-NLRP3 inflammasome complexes and their application in the treatment of acute and chronic inflammation-related diseases (82173675), 2022.01~2025.12, RMB 550,000, principal investigator, ongoing.

 

  • National Natural Science Foundation of China, Youth Program: Discovery, design, synthesis, and exploration of NLRP3 inflammasome-targeted inhibitors for the treatment of non-controllable inflammatory disorders (81803354). 2019.01~2021.12, RMB 210,000, principal investigator, completed.

 

  • Natural Science Foundation of Jiangsu Province, Youth Program: Design and synthesis of NLRP3-targeted inhibitors based on skeleton reconstruction strategy, and exploration of their therapeutic effects on non-controllable inflammatory disorders (BK20180564). 2018.07~2021.06, RMB 200,000, principal investigator, completed.

 

  • Natural Science Foundation of Jiangsu Province, General Program: Discovery, design, synthesis, and activity evaluation of novel inhibitors targeting TLR4-MD2 immune-inflammatory pathway for drug addiction treatment (BK20231480). 2023-07-01~2026-06-30, RMB 100,000, principal investigator, ongoing.
  • China Postdoctoral Science Foundation, General Program: Discovery, optimization, activity evaluation, and mechanistic studies of ULK1 inhibitors (2017M620232), 2018.01~2021.01, RMB 80,000, principal investigator, completed.

 

  • Fundamental Research Funds for the Central Universities, Key Program: Discovery and validation of novel oxadiazole-based anti-inflammatory target proteins using proteomics and molecular probe technology, 2021.01~2022.12, RMB 150,000, principal investigator, ongoing.

 

  • National Natural Science Foundation of China, General Program: Discovery of ubiquitin E3 ligase Cbl-b inhibitors based on substrate-binding crucial features and exploration of their application in tumor immunotherapy (82173680), 2022.01~2025.12, RMB 550,000, ongoing, participating.

 

  • National Natural Science Foundation of China, General Program: Discovery of targeted inducers of tau protein degradation conjugates based on ubiquitin E3 ligase Keap1 and exploration of their therapeutic application in Alzheimer’s disease (81773581), 2018.01~2021.12, RMB 620,000, completed, participating.

 

  • National Natural Science Foundation of China, Youth Program: Research on the application of GNN-based Raman hotspot regulation method in drug-target interaction (81803485), 2019.01~2021.12, RMB 210,000, completed, participating.

🏭 Consultancy/Industry Projects:

  • Institutional commissioned project: Detection of drugs in urban wastewater in Jiangyin City, commissioned by the Jiangyin Public Security Bureau, RMB 69,100, principal investigator, ongoing.
  • Industry commissioned project: Joint laboratory for drug detection between China Pharmaceutical University and Jiangsu Kangda Detection Technology Co., Ltd. (co-build laboratory), RMB 200,000, principal investigator, ongoing.

πŸ“š Books Published (ISBN):

Currently, no books have been published.

πŸ’‘ Patents Published/Under Process:

As the first inventor, Lili Xu has obtained 5 granted invention patents; as the fourth inventor, she has obtained 1 granted invention patent. Patent numbers: ZL201911146468.0, ZL202110442073.6, ZL202010483840.3, ZL201910366733.X, ZL202210071005.8, ZL202210146811.7.

.

πŸŽ“Publication Top Noted:

Paper Title : Development of fentanyl-specific monoclonal antibody (mAb) to antagonize the pharmacological effects of fentanyl
    • Authors:Jun Huang, Xing-Xing Fan, Jiaxi He, Hui Pan, Run-Ze Li, Liyan Huang, Zebo Jiang, Xiao-Jun Yao, Liang Liu, Elaine Lai-Han Leung, Jian-Xing Hee
    • Journal: Oncotarget
    • Year:2016
    • Citations : 86

     

Paper Title :The NLRP3 inflammasome: a vital player in inflammation and mediating the anti-inflammatory effect of CBD
  • Authors: Chu, F.-X., Wang, X., Li, B., Xu, L.-L., Di, B.
  • Journal: Inflammation Research
  • Volume: In Press
  • Issue: In Press
  • Year: 2024
Paper Title : Protein-protein interactions and related inhibitors involved in the NLRP3 inflammasome pathway
  • Authors: Ma, Z.-Y., Jiang, C., Xu, L.-L.
  • Journal: Cytokine and Growth Factor Reviews
  • Volume: 74
  • Pages: 14–28
  • Year: 2023
Paper Title :Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors
  • Authors: Ye, T., Tao, W.-Y., Chen, X.-Y., Di, B., Xu, L.-L.
  • Journal: Cytokine and Growth Factor Reviews
  • Volume: 74
  • Pages: 1–13
  • Year: 2023
Paper Title : A light-up fluorescence probe for wash-free analysis of Mu-opioid receptor and ligand-binding events
  • Authors: Jia, Y., Xu, L., Wang, L., Yan, F., Hu, C.
  • Journal: Analytica Chimica Acta
  • Volume: 1261
  • Pages: 341220
  • Year: 2023